Marker Therapeutics, Inc.

Monthly Archives: July 2016

TapImmune Appoints Dr. John N. Bonfiglio as President and Chief Operating Officer

…JACKSONVILLE, Florida, July 19, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today that the Company has appointed Dr. John N. Bonfiglio, a member of its Board of Directors, as the Company’s President and Chief Operating Officer.

Read More